REVUMENIB CITRATE - Generic Drug Details

What are the generic drug sources for revumenib citrate and what is the scope of patent protection?

Revumenib citrate is the generic ingredient in one branded drug marketed by Syndax and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Revumenib citrate has forty patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for REVUMENIB CITRATE

International Patents:	40
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	REVUMENIB CITRATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REVUMENIB CITRATE

Constraining patent/regulatory exclusivity:

TREATMENT OF RELAPSED OR REFRACTORY MIXED-PHENOTYPE ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER.

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for REVUMENIB CITRATE

Drug Class	Menin Inhibitor
Mechanism of Action	Menin Inhibitors

US Patents and Regulatory Information for REVUMENIB CITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Syndax	REVUFORJ	revumenib citrate	TABLET;ORAL	218944-002	Nov 15, 2024		RX	Yes	No	10,683,302		Y	Y
Syndax	REVUFORJ	revumenib citrate	TABLET;ORAL	218944-002	Nov 15, 2024		RX	Yes	No
Syndax	REVUFORJ	revumenib citrate	TABLET;ORAL	218944-002	Nov 15, 2024		RX	Yes	No	11,479,557		Y
Syndax	REVUFORJ	revumenib citrate	TABLET;ORAL	218944-002	Nov 15, 2024		RX	Yes	No
Syndax	REVUFORJ	revumenib citrate	TABLET;ORAL	218944-001	Nov 15, 2024		RX	Yes	No	10,683,302		Y	Y

International Patents for REVUMENIB CITRATE

Country	Patent Number	Title	Estimated Expiration
Canada	3024180
China	109743875
Brazil	122024002146
Brazil	112018075260
Mexico	2018015252	INHIBIDORES DE LA INTERACCION DE MENINA-LEUCEMIA DE LINAJE MIXTO. (INHIBITORS OF THE MENIN-MLL INTERACTION.)

Market Dynamics and Financial Trajectory for Revumenib Citrate

Last updated: July 31, 2025

---

Introduction

Revumenib citrate, an orally administered selective inhibitor of the menin-MLL interaction, has garnered significant attention within the oncology therapeutic landscape, particularly for acute leukemia subtypes driven by MLL (mixed-lineage leukemia) gene rearrangements. As a novel agent in targeted cancer therapy, understanding its market potential, competitive positioning, and financial trajectory is essential for pharmaceutical companies, investors, and stakeholders navigating this promising yet complex segment.

---

Mechanism of Action and Therapeutic Indication

Revumenib citrate operates by disrupting the menin-MLL protein-protein interaction, thereby reversing aberrant transcriptional programs that underpin leukemogenesis in MLL-rearranged leukemia. The specificity of this mechanism positions Revumenib as a potentially transformative treatment for patients with limited therapeutic options, often characterized by poor prognosis and resistant disease profiles (1).

The primary indication focuses on relapsed/refractory acute leukemias harboring MLL gene rearrangements, predominantly affecting adult and pediatric populations. Its utilization may expand to other hematological malignancies characterized by similar epigenetic dysregulation, further broadening its therapeutic reach.

---

Market Landscape and Competitive Environment

The global acute myeloid leukemia (AML) market, estimated to reach $1.5 billion by 2027 (2), comprises a mix of chemotherapy, targeted therapies, and immunotherapies. The emergence of menin inhibitors like Revumenib positions the drug as a first-in-class agent within the niche of epigenetic and protein-protein interaction inhibitors.

Key competitors include:

• SNDX-5613 (Stemline Therapeutics): another menin inhibitor in clinical development.
• Bomedemstat (IMG-7289): targeting other epigenetic pathways.
• Other epigenetic agents and combination therapies, including FLT3 inhibitors and immunotherapies.

The competitive environment hinges on factors like clinical efficacy, safety profile, biomarker specificity, and regulatory approval timelines. Revumenib's differentiation rests on its potency and oral administration, which could favor its uptake compared to parenterally administered alternatives.

---

Regulatory and Developmental Milestones

Revumenib citrate has progressed through pivotal clinical trials, notably the Phase 1/2 trial (clinicaltrials.gov NCT04065399). Preliminary data demonstrated promising remission rates in heavily pretreated patients, fueling optimism for accelerated regulatory pathways.

The FDA granted Breakthrough Therapy Designation, emphasizing the drug’s potential impact on unmet needs in MLL-rearranged leukemia (3). Such designation expedites review processes, potentially enabling accelerated approval within the next 12-24 months, subject to confirmatory trial outcomes.

---

Financial Trajectory and Market Penetration

Revenue Forecasts and Commercial Strategy

Early revenue potential hinges on successful trial outcomes, regulatory approvals, and market adoption. For a first-in-class targeted agent, initial sales are often modest but can accelerate rapidly post-approval due to high unmet medical needs.

Analysts project peak sales in the range of $300-$500 million globally within 7-10 years post-launch, contingent on:

• Market Penetration Rate: Adoption by hematologists and oncologists based on clinical data.
• Pricing Strategy: Premium pricing aligned with novel mechanism and orphan designation status.
• Pricing Benchmarks: Similar targeted drugs in oncology have achieved per-dose prices exceeding $10,000 (4).

Cost Dynamics include ongoing R&D investments to confirm efficacy across broader indications, manufacturing scale-up, and post-marketing surveillance expenses.

Risks such as failure of confirmatory trials or regulatory setbacks could significantly dampen revenue prospects. Conversely, successful registration and favorable reimbursement approvals could unlock substantial value.

---

Regulatory and Economic Considerations

The regulatory environment emphasizes expedited pathways for breakthrough therapies, combined with risk-sharing reimbursement models due to high drug prices. Reimbursement negotiations will depend on demonstrated clinical benefit and economic impact—namely, reduction in healthcare costs associated with prolonged survival and decreased hospitalization.

Patent protection, expected to last until at least 2035, secures the commercial window. Generic and biosimilar competition are unlikely due to the nature of the molecule and patent landscape.

---

Market Adoption Factors

The adoption of Revumenib in clinical practice depends on several factors:

• Clinical efficacy: Response rates, durability of remission.
• Safety profile: Tolerability impacts prescribing confidence.
• Physician familiarity: Educational outreach and access to clinical trial data.
• Companion diagnostics: Use of molecular testing for patient selection enhances targeted therapy adoption.

Synergies with combination therapies could further expand its market footprint, driven by ongoing research into synergistic regimens.

---

Future Outlook and Strategic Considerations

The broader landscape suggests a strategic positioning of Revumenib as an integral part of precision hematology. Its success will depend on:

• Continued clinical validation and potential label expansions.
• Market access advancement through partnerships and reimbursement strategies.
• Competitive differentiation involving dosing convenience, biomarker-driven approach, and safety.

Investment in predictive biomarkers may optimize patient selection, enhancing both clinical and economic outcomes.

---

Key Takeaways

• Revumenib citrate is poised to disrupt the MLL-rearranged leukemia treatment paradigm, with a clear pathway toward regulatory approval.
• Market potential is substantial within the niche of epigenetic-targeting leukemia therapies, with expectations of reaching $300-$500 million peak sales.
• Regulatory advantages via breakthrough therapy designation could accelerate market entry, while pricing strategies will be critical.
• Competitive landscape remains limited but is rapidly evolving; differentiation through clinical data and safety is pivotal.
• Success depends on robust clinical validation, effective commercialization, and navigating reimbursement pathways.

---

FAQs

1. When is Revumenib citrate expected to receive regulatory approval?
Pending positive clinical trial results and submission of dossiers, regulatory agencies like the FDA could approve Revumenib within 12-24 months, especially given its Breakthrough Therapy designation.

2. What specific patient population will Revumenib target initially?
It is primarily aimed at patients with relapsed/refractory MLL-rearranged acute leukemia, which constitutes a small but high-need segment within AML.

3. How does Revumenib compare to existing therapies?
Revumenib’s targeted mechanism offers potentially higher efficacy with a favorable safety profile over traditional chemotherapies, though comparative data are still forthcoming.

4. What are the primary challenges in commercializing Revumenib?
Key challenges include demonstrating long-term efficacy, managing costs and pricing, securing reimbursement, and establishing clinician familiarity.

5. What is the outlook for Revumenib’s market expansion?
Positive initial results may lead to label expansion into other MLL-related disorders and combination therapy areas, broadening its commercial scope over time.

---

Sources:
[1] Clinical trial data, NCT04065399.
[2] MarketsandMarkets, “Leukemia Therapeutics Market,” 2022.
[3] FDA Breakthrough Therapy Designation announcement.
[4] IBM Watson Health, “Oncology Drug Pricing,” 2022.